Worth reading
84Important
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
2269
¥100 million (year-on-year increase in revenue)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFiscal year ended March 2026 (fiscal 2025)9 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales21,392 Hundreds of millions of yen+11.9%
Operating profit3,826 Hundreds of millions of yen+832.4%
Net income2,916 Hundreds of millions of yen+474.6%
Operating profit margin17.9 %
Selling, general and administrative expenses8,603 Hundreds of millions of yen
Full-year earnings forecast
Target fiscal yearFiscal year ending March 2027 (fiscal 2026)
Revenue
22,200 Hundreds of millions of yen
Selling, general and administrative expenses
8,000 Hundreds of millions of yen
Research and development costs
3,550 Hundreds of millions of yen
Core operating profit
6,200 Hundreds of millions of yen
Operating profit
3,950 Hundreds of millions of yen
Dividend per share
¥80
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
RevenueGrowth in key strategic products: approximately +¥140 billion
Selling, general and administrative expenses (excluding foreign exchange effects)Investment in key strategic products: approximately +¥10 billion; cost optimization through SMT: approximately ¥11 billion
Research and development expenses (excluding foreign exchange effects)Pipeline development expenses: approximately +¥5 billion; cost optimization through SMT: approximately ¥10 billion; reduction in development expenses for key strategic products: approximately -¥5 billion
Cumulative SMT cost savingsApproximately ¥25 billion
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Exchange rate¥150 to the U.S. dollar and ¥180 to the euro (average during the period)
Increase in sales of key strategic productsApproximately +¥130 billion
Decrease in XTANDI salesApproximately -¥50 billion
SMT cost savingsApproximately ¥40 billion
Increase in R&D expenses from new Phase III trials and other activitiesIncrease mainly in clinical development expenses
New initiatives
- Plan to start the Phase III EV-309 trial of MIBC bladder-preserving therapy
- Plan to start Phase III trials of setidegrasib and ASP2138
- Advance the development of new clinical programs, including ASP2998 and ASP2957
- In-license external assets, including ASP546C and VIR-5500
- Pursue cumulative cost savings of ¥150 billion through SMT
Key KPIsA metric the company considers important as a management benchmark.
- Revenue from key strategic products4,803 Hundreds of millions of yenYear on year against the same period last year+43%
- Growth in key strategic products1,439 Hundreds of millions of yen
- IZERVAY treatment rate with complement inhibitors20 Approximately %
- Number of PoC achievements in fiscal 20253 Engagements
- Number of programs entering clinical development12 Program
- SMT cost savings250 Hundreds of millions of yen
Medium-term management plan targets
RevenueFiscal 2025 sales of XTANDI and key strategic products of at least ¥1.2 trillion
Pipeline valueAt least ¥500 billion in sales in fiscal 2030 from Focus Area projects
Core operating marginAt least 30% in fiscal 2025
Comparison with actual resultsTotal sales of at least ¥1.4 trillion, core operating margin of 26.0%, and ¥65 billion in cost savings
Financial targets
Gross Debt/EBITDAAn appropriate level is 1.0–1.5x, with 3.0x as a guideline for the upper limit during large-scale investments
Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
800 Hundreds of millions of yen
DetailsOther expenses include risks related to impairment losses and costs associated with organizational restructuring.
Annual Dividend
Annual dividend amount
¥80 per share
Acquisition of treasury shares
The policy is to conduct share repurchases flexibly when excess funds arise. The repurchase authorization, number of shares and period are not disclosed.| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | Fiscal year ended March 2026 (fiscal 2025) |
| Net Sales | 21,392 Hundreds of millions of yen (YoY +11.9%) |
| Operating profit | 3,826 Hundreds of millions of yen (YoY +832.4%) |
| Net income | 2,916 Hundreds of millions of yen (YoY +474.6%) |
| Operating profit margin | 17.9 % |
| Selling, general and administrative expenses | 8,603 Hundreds of millions of yen |
| Full-year earnings forecast | Target fiscal year Fiscal year ending March 2027 (fiscal 2026) / Revenue 22,200 Hundreds of millions of yen / Selling, general and administrative expenses 8,000 Hundreds of millions of yen / Research and development costs 3,550 Hundreds of millions of yen / Core operating profit 6,200 Hundreds of millions of yen / Operating profit 3,950 Hundreds of millions of yen / Dividend per share ¥80 |
| Breakdown of Factors Affecting the Change | Revenue Growth in key strategic products: approximately +¥140 billion / Selling, general and administrative expenses (excluding foreign exchange effects) Investment in key strategic products: approximately +¥10 billion; cost optimization through SMT: approximately ¥11 billion / Research and development expenses (excluding foreign exchange effects) Pipeline development expenses: approximately +¥5 billion; cost optimization through SMT: approximately ¥10 billion; reduction in development expenses for key strategic products: approximately -¥5 billion / Cumulative SMT cost savings Approximately ¥25 billion |
| Key KPIs | Indicator name Revenue from key strategic products / Value 4,803 Hundreds of millions of yen / Year on year against the same period last year +43%, Indicator name Growth in key strategic products / Value 1,439 Hundreds of millions of yen / Year on year against the same period last year Not disclosed, Indicator name IZERVAY treatment rate with complement inhibitors / Value 20 Approximately % / Year on year against the same period last year Not disclosed, Indicator name Number of PoC achievements in fiscal 2025 / Value 3 Engagements / Year on year against the same period last year Not disclosed, Indicator name Number of programs entering clinical development / Value 12 Program / Year on year against the same period last year Not disclosed, Indicator name SMT cost savings / Value 250 Hundreds of millions of yen / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | Exchange rate ¥150 to the U.S. dollar and ¥180 to the euro (average during the period) / Increase in sales of key strategic products Approximately +¥130 billion / Decrease in XTANDI sales Approximately -¥50 billion / SMT cost savings Approximately ¥40 billion / Increase in R&D expenses from new Phase III trials and other activities Increase mainly in clinical development expenses |
| Risk amount incorporated into the outlook | 800 Hundreds of millions of yen |
| Medium-term management plan targets | Revenue Fiscal 2025 sales of XTANDI and key strategic products of at least ¥1.2 trillion / Pipeline value At least ¥500 billion in sales in fiscal 2030 from Focus Area projects / Core operating margin At least 30% in fiscal 2025 / Comparison with actual results Total sales of at least ¥1.4 trillion, core operating margin of 26.0%, and ¥65 billion in cost savings |
| Financial targets | Gross Debt/EBITDA An appropriate level is 1.0–1.5x, with 3.0x as a guideline for the upper limit during large-scale investments |
| Annual Dividend | Annual dividend amount ¥80 per share / Breakdown Not disclosed |
| Acquisition of treasury shares | The policy is to conduct share repurchases flexibly when excess funds arise. The repurchase authorization, number of shares and period are not disclosed. |
| New initiatives | Plan to start the Phase III EV-309 trial of MIBC bladder-preserving therapy, Plan to start Phase III trials of setidegrasib and ASP2138, Advance the development of new clinical programs, including ASP2998 and ASP2957, In-license external assets, including ASP546C and VIR-5500, Pursue cumulative cost savings of ¥150 billion through SMT |
Items this document does not state (14)
Ordinary incomeGross Profit MarginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesPayout ratioCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main factors were expanded sales of key strategic products, cost optimization of selling, general and administrative expenses, research and development expenses and cost of sales through SMT (Sustainable Margin Transformation), and expense management. In fiscal 2026, growth in key strategic products and SMT-driven cost optimization are expected to drive growth in core operating profit.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.